Abstract
Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.
| Original language | English |
|---|---|
| Pages (from-to) | 1396-1398 |
| Number of pages | 3 |
| Journal | Pediatric Blood and Cancer |
| Volume | 55 |
| Issue number | 7 |
| DOIs | |
| State | Published - Dec 2010 |
| Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Oncology
- Pediatrics, Perinatology, and Child Health
- Hematology
Fingerprint Dive into the research topics of 'Treatment of childhood kaposiform hemangioendothelioma with sirolimus'. Together they form a unique fingerprint.
Cite this
Blatt, J., Stavas, J., Moats-Staats, B., Woosley, J., & Morrell, D. S. (2010). Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatric Blood and Cancer, 55(7), 1396-1398. https://doi.org/10.1002/pbc.22766